Provided by Tiger Trade Technology Pte. Ltd.

Armata Pharmaceuticals, Inc.

5.23
-0.1800-3.33%
Volume:33.40K
Turnover:181.44K
Market Cap:194.46M
PE:-0.99
High:5.68
Open:5.54
Low:5.23
Close:5.41
52wk High:16.34
52wk Low:2.86
Shares:37.18M
Float Shares:11.88M
Volume Ratio:1.78
T/O Rate:0.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.2744
EPS(LYR):-4.8000
ROE:-3439.35%
ROA:-25.83%
PB:-0.84
PE(LYR):-1.09

Loading ...

Armata Pharmaceuticals CEO Deborah Birx Presents at H.C. Wainwright Global Investment Conference

Reuters
·
Yesterday

Armata Says Inhaled Phage Candidate AP-PA02 Completes Phase 2 Trials in Cystic Fibrosis, Bronchiectasis Patients

Reuters
·
Sep 03

Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate

Benzinga Earnings
·
Aug 13

Armata Swings to FY26 Q2 Net Income of $74.14 Million; Operating Loss Widens to $10.31 Million

Reuters
·
Aug 13

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

THOMSON REUTERS
·
Aug 13

Armata Pharmaceuticals, - Promotes David House to Chief Financial Officer

THOMSON REUTERS
·
Aug 13

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Armata Pharmaceuticals (ARMP)

TIPRANKS
·
Jul 20

Armata Pharmaceuticals - Appoints David House as Chief Financial Officer Effective July 17, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 20

Armata provides update on AP-SA02 studies

TIPRANKS
·
Jul 20

Armata Pharmaceuticals Names David House CFO

Reuters
·
Jul 20

Armata Pharmaceuticals Announces Press Release Availability

Reuters
·
Jul 13

Armata Wins FDA Agreement on Pediatric Study Plan for Ap-sa02 in Complicated S. Aureus Bacteremia

Reuters
·
Jul 13

Armata Pharmaceuticals - Adult Phase 3 Study for Ap-sa02 Expected to Initiate in Second Half of 2026

THOMSON REUTERS
·
Jul 13

Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for Ap-sa02 for the Treatment of Complicated Staphylococcus Aureus Bacteremia

THOMSON REUTERS
·
Jul 13

Armata Pharmaceuticals - FDA Defers Pediatric Studies for Ap-sa02 Until Adult Phase 3 Data Generated

THOMSON REUTERS
·
Jul 13

Armata Pharmaceuticals - FDA Agreement Establishes Regulatory Framework for Ap-sa02 in Pediatric SAB

THOMSON REUTERS
·
Jul 13

Armata Pharma Amends 8-K to Disclose Director Daniel Gilmer Committee Assignment

Reuters
·
Jun 25

Sector Update: Healthcare Stocks Mixed Pre-Bell Tuesday

MT Newswires Live
·
Jun 23

Armata Pharmaceuticals Shares Rise on Additional $2.5M Government Grant

Dow Jones
·
Jun 23

Armata Pharmaceuticals receives additional USD 2.5 million DoD funding for AP-SA02 program

Reuters
·
Jun 23